Logo for Aracari
Logo for Aracari

Aracari Biosciences wins Startup World Cup Southern California 2022

IRVINE, CA, August 11th, 2022 – Aracari Biosciences, Inc. (“Aracari”) announced that it has won the Startup World Cup Southern California held on August 11th, 2022, in Malibu, CA. The event was organized by Pegasus Tech Ventures in San Jose, CA, in partnership with LA Venture Association and the Pepperdine University Graziadio Business School. In addition to the championship trophy, Aracari wins the opportunity to pitch at the Grand Finale in Silicon Valley on September 30th, 2022, alongside the 70+ regional champions from 6 continents. These regional winners around the world will compete at the Grand Finale in San Francisco September 30th, 2022. The winner will receive a US $1M investment prize.

This competition was co-sponsored by Republic Bank and SAM Precellerator. The judges were Mr. Winston Damarillo from Talino Ventures, Mr. James Shector from Fika Ventures and Ms. Yi Wen Li from Alumni Ventures. Startup World Cup is one of the biggest and richest startup competitions in the world, with the goal of supporting regional innovation ecosystems and connecting them to Silicon Valley.

“We are really excited to receive this award and to have the opportunity to present our TumorChip™ personalized oncology platform at the Grand Finale,” said Dr. Chris Hughes, a scientific founder of Aracari. “We are very honored that these esteemed venture capital veterans recognize the vast potential of Aracari’s all human vascularized TumorChip™ to discover truly-personalized cancer therapies,” said Dr. Wes Hatfield, chairman and a co-founder of Aracari.

About Aracari Biosciences, Inc.

Aracari’s mission is to accelerate drug development and tailor treatments to individual patients by using the greater accuracy of its microphysiological platforms to predict drug reactions in humans. Patient tumor samples grow 3-dimensionally in Aracari’s TumorChip™, which uses living, perfused human blood vessels to deliver nutrients, drugs, and immune cells into the microenvironment of the patient’s tumor, just as they are delivered in the human body. Aracari’s powerful next-generation tools already are advancing discovery in immuno-oncology therapies and drug development for multiple cancer types.

Ming-I Huang